ActivePure Medical, LLC has been awarded a national group purchasing agreement for Facility Surface and Air Disinfection Technology with Premier, Inc. through its Technology Breakthroughs Program.
ActivePure Medical notes effective Feb. 1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for ActivePure Medical’s continuous, whole-room automated air and surface disinfection technology.
ActivePure Medical, the exclusive healthcare provider of ActivePure Technology, was created in 2020 after receiving clearance from the U.S. Food and Drug Administration (FDA) on their Class II Medical Device, the ActivePure Medical Guardian. The medical-grade device uses ActivePure’s patented and proprietary technology to create effective molecules that continuously fill the environment of care where they reduce airborne and surface pathogens.
“We are very excited to announce our Breakthrough status with Premier and to be awarded a GPO agreement. This national agreement allows ActivePure Medical to supply members with the best whole-room, automated surface and air disinfection technology developed for facility-wide coverage,” said ActivePure Medical President Dan Marsh. “Premier is a leader in the healthcare industry with a large network of health systems and members throughout the continuum of care, and we appreciate the company evaluating and awarding innovative technologies, like ActivePure, to ensure their members have access to the newest technologies available.”
All ActivePure Medical products were specifically designed for healthcare settings and have received California Air and Resource Board (CARB) Certification for no ozone production. ActivePure Medical will offer products to Premier customers that can be utilized in their current HVAC systems or portable units that are plug and play with no installation required. ActivePure Medical understands the staffing concerns of all healthcare facilities and developed its units to run automatically without an operator for 6-months or more.
The surge in COVID-19 cases has continued to result in not only significant shortages in healthcare staffing, but recent Centers for Disease Control and Prevention (CDC) data has shown that healthcare-associated infections (HAIs) have increased for the first time since 2015. Besides reducing Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Erwinia herbicola, Aspergillus niger, Bacillus globigii and Fungi, and other clinically relevant pathogens, ActivePure is extremely effective against SARS-CoV-2 responsible for COVID-19. The latest independent testing found ActivePure inactivated more than 99.98% of high concentration levels of the enveloped virus in one minute. All data can be found on the ActivePure Medical website, www.ActivePureMedical.com
